When is the next QNCX stock earnings or update date?

Quince Therapeutics lists its next earnings and company update for **Mar 23, 2026**; investors watch for clinical progress, cash runway commentary, and potential partnering news ahead of that date.

What is the Meyka AI rating and short-term view on QNCX stock?

Meyka AI rates QNCX **67.39/100 (Grade B, HOLD)**. The model flags mixed fundamentals with possible upside should clinical or partnership news arrive, but also high dilution and volatility risk.

What drives the biggest upside or downside for QNCX stock?

Upside depends on positive clinical data, licensing or partnership deals, or improved cash guidance. Downside risks include continued burn, dilution, or trial setbacks; trading is sensitive around earnings windows.

What price targets and forecast exist for QNCX stock?

Meyka AI’s model projects a quarterly target of **$1.38** (model projection) and we outline a conservative **$0.05**, base **$0.30**, and bull **$1.38** scenario. Forecasts are projections, not guarantees.

US Stocks

QNCX Quince Therapeutics (NASDAQ) $0.099 intraday 18 Mar 2026: earnings Mar 23 could reset outlook

ByDanny Kontos March 18, 2026

Quince Therapeutics (QNCX stock) trades at $0.099 intraday on the NASDAQ as investors position ahead of the company’s earnings announcement on Mar 23, 2026. Volume is active at 10,519,528 shares and the share price is down 4.81% today, reflecting heavy selling versus the 50-day average of $1.20. With no product revenue recorded and key clinical milestones expected, this earnings window could change valuations quickly. We track cash, debt, analyst signals and technicals to frame risk and opportunity for traders and longer-term holders.